- Home
- BCDA vs APRE Comparison
BCDA vs APRE Comparison
Compare BCDA & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCDA
- APRE
- Stock Information
- Founded
- BCDA N/A
- APRE 2006
- Country
- BCDA United States
- APRE United States
- Employees
- BCDA N/A
- APRE N/A
- Industry
- BCDA Biotechnology: Pharmaceutical Preparations
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BCDA Health Care
- APRE Health Care
- Exchange
- BCDA Nasdaq
- APRE Nasdaq
- Market Cap
- BCDA 10.1M
- APRE 10.0M
- IPO Year
- BCDA N/A
- APRE 2019
- Fundamental
- Price
- BCDA $2.35
- APRE $1.89
- Analyst Decision
- BCDA Strong Buy
- APRE Strong Buy
- Analyst Count
- BCDA 1
- APRE 2
- Target Price
- BCDA $25.00
- APRE $15.50
- AVG Volume (30 Days)
- BCDA 238.1K
- APRE 50.1K
- Earning Date
- BCDA 08-12-2025
- APRE 08-11-2025
- Dividend Yield
- BCDA N/A
- APRE N/A
- EPS Growth
- BCDA N/A
- APRE N/A
- EPS
- BCDA N/A
- APRE N/A
- Revenue
- BCDA $3,000.00
- APRE $1,284,475.00
- Revenue This Year
- BCDA N/A
- APRE N/A
- Revenue Next Year
- BCDA N/A
- APRE N/A
- P/E Ratio
- BCDA N/A
- APRE N/A
- Revenue Growth
- BCDA N/A
- APRE 33.27
- 52 Week Low
- BCDA $1.63
- APRE $1.41
- 52 Week High
- BCDA $4.66
- APRE $5.01
- Technical
- Relative Strength Index (RSI)
- BCDA 54.75
- APRE 55.82
- Support Level
- BCDA $2.22
- APRE $1.60
- Resistance Level
- BCDA $2.42
- APRE $2.22
- Average True Range (ATR)
- BCDA 0.13
- APRE 0.17
- MACD
- BCDA 0.01
- APRE 0.03
- Stochastic Oscillator
- BCDA 72.97
- APRE 46.77
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.